Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulcrum Therapeutics Inc (NQ: FULC )

3.165 +0.195 (+6.57%)
Streaming Delayed Price Updated: 11:29 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
FULC INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FULC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
Looking Into Fulcrum Therapeutics's Return On Capital Employed
Via Benzinga
Fulcrum Therapeutics's Earnings Outlook
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fulcrum, and adidas and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fulcrum Therapeutics, Inc. (FULC) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)
From Bernstein Liebhard LLP
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fulcrum Therapeutics, Inc. (FULC) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
FULC EQUITY ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FULC
From Rosen Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fulcrum Therapeutics, Inc. (FULC) Investors
From Law Offices of Howard G. Smith
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
FULCRUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fulcrum Therapeutics, Inc. (FULC)
From Robbins LLP
Via Business Wire
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces CFO Resignation
Rajavelu to continue supporting Fulcrum in a consulting capacity 
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
NASDAQ:FULC Shareholder Notice: Investigation over Possible Securities Laws Violations by Fulcrum Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 03/14/2023 -- Fulcrum Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
Via Benzinga
United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday
Piper Sandler raised the price target for Riskified Ltd. (NYSE: RSKD) from $6 to $8. Piper Sandler analyst Brent Bracelin upgraded the stock from Neutral to Overweight. Riskified shares rose 2.4% to... 
Via Benzinga
Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Dow Up 150 Points; US Weekly Jobless Claims Rise
U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Thursday. Following the market opening Thursday, the Dow traded up 0.46% to 32,948.78 while the NASDAQ rose 0.27%... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
FULCRUM ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulcrum Therapeutics, Inc. on Behalf of Fulcrum Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fulcrum Therapeutics, Inc. (FULC) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.